Genomics-based testing brand Genetic Technologies Limited (ASX:GTG, NASDAQ:GENE, OTC:GNTLF) is expanding its international presence and trialling new methods of reaching an audience, with a pilot influencer campaign fuelling sales.
New international markets
The company’s profile rose in the second quarter of 2024 on the back of the introduction of the GeneType suite of genetic risk assessment tests to Canada and New Zealand.
This expansion follows on the heels of its recent entry into the US market through a partnership with health and wellness technology leader Stayhealthy Inc.
The GeneType risk assessment test will be distributed in these newest markets through Stayhealthy Canada and Stayhealthy New Zealand.
Full-scale marketing campaign
The expansion coincides with the company’s recent success in its digital transformation strategy and a pilot influencer campaign with Creators Entertainment Group that has generated a 500% increase in week-over-week sales.
“We are anticipating accelerated growth as we enter Canada and New Zealand,” said CEO Simon Morriss.
“Coupled with our expansion into new territories, our full-scale marketing efforts have successfully increased consumer awareness and trust, translating into unprecedented growth.”
About Genetic Technologies
The first GeneType assessment for breast cancer was developed in 2022 after 20 years of research stemming from GTG’s significant contributions to the Human Genome Project.
The company has since developed a comprehensive suite of innovative tests evaluating genetic and traditional risk for nine specific metabolic, cardiovascular and oncological diseases covering 70% of annual mortality and morbidities: melanoma, breast, ovarian, colorectal, pancreatic and prostate cancer, coronary artery disease, atrial fibrillation (AFib) and Type 2 diabetes.
Uniquely, the GeneType assessment goes a step further to help mitigate risk by delivering actionable recommendations that allow individuals to proactively take control of their health.
Clinical-grade assessments for new cancers and chronic conditions are in development.
GeneType’s non-invasive, easy-to-use, saliva-based tests are clinically validated and regulatory approved.